Effect of butyrate‐producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumab

AIM: Multiple studies have revealed the correlation between gut microbiome and the response to checkpoint inhibitors (CPIs) in patients with cancer, and oral administration of butyrate‐producing enterobacteria has been reported to enhance the efficacy of CPIs. However, the effects of enterobacteria...

Descripción completa

Detalles Bibliográficos
Autores principales: Nouso, Kazuhiro, Shiota, Shohei, Fujita, Rio, Wakuta, Akiko, Kariyama, Kazuya, Hiraoka, Atsushi, Atsukawa, Masanori, Tani, Joji, Tada, Toshifumi, Nakamura, Shinichiro, Tajiri, Kazuto, Kaibori, Masaki, Hirooka, Masashi, Itobayashi, Ei, Kakizaki, Satoru, Naganuma, Atsushi, Ishikawa, Toru, Hatanaka, Takeshi, Fukunishi, Shinya, Tsuji, Kunihiko, Kawata, Kazuhito, Takaguchi, Koichi, Tsutsui, Akemi, Ogawa, Chikara, Ochi, Hironori, Yata, Yutaka, Kuroda, Hidekatsu, Iijima, Hiroko, Matono, Tomomitsu, Shimada, Noritomo, Yasuda, Satoshi, Toyoda, Hidenori, Kumada, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10523959/
https://www.ncbi.nlm.nih.gov/pubmed/37563961
http://dx.doi.org/10.1002/cam4.6416

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10523959/
https://www.ncbi.nlm.nih.gov/pubmed/37563961
http://dx.doi.org/10.1002/cam4.6416

Ejemplares similares